As ustekinumab is increasingly used earlier in Crohn’s disease (CD), evidence regarding the effectiveness of subsequent anti-tumor necrosis factor (TNF) therapy remains limited. We compared anti-TNF outcomes after prior ustekinumab exposure with first-line anti-TNF therapy in biologic-naïve patients.
We co...
Jia-Wei Zhan, Wei-Yan Feng, Na Diao et al.· BMC Gastroenterology· 0 citations
BACKGROUND
Intestinal ultrasound (IUS) is increasingly used to monitor activity and predict treatment outcomes in Crohn's disease (CD), but its role in predicting primary non-response (PNR) to Upadacitinib (UPA) and identifying maintenance relapse remains unclear.
METHODS
In this multicenter prospective cohort study,...
Ren-Bin He, Yuan-Yuan Huang, Jing Han et al.· Alimentary Pharmacology and...· 0 citations
Complete mucosal healing is a key therapeutic goal in inflammatory bowel disease (IBD). While ferroptosis-mediated epithelial cell death is known to compromise the mucosal barrier as the cornerstone of mucosal healing, the precise mechanisms driving this process during IBD pathogenesis remain to be fully elucidated...
Jing Han, Xiao-Ling Li, Ying Wang et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.